Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrative Proteomics and N-Glycoproteomics Reveals the Synergistic Anti-tumor Effects of Aspirin and Gemcitabine-based Chemotherapy on Pancreatic Cancer Cells

ABSTRACT: Based on an integrated multi-omics based on quantitative N-glycoproteomes analysis strategy, we investigated their synergistic anti-tumor effects and explored the potential molecular mechanisms and biological functions underlying their inhibitory effects on the development of pancreatic cancer.

ORGANISM(S): Homo Sapiens

SUBMITTER: Wantao Ying

PROVIDER: PXD041445 | iProX | Mon Apr 10 00:00:00 BST 2023

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Integrative proteomics and n-glycoproteomics reveal the synergistic anti-tumor effects of aspirin- and gemcitabine-based chemotherapy on pancreatic cancer cells.

Li Xiaoyu X Kong Ran R Hou Wenhao W Cao Junxia J Zhang Li L Qian Xiaohong X Zhao Lijiao L Ying Wantao W

Cellular oncology (Dordrecht, Netherlands) 20230828 1

<h4>Objective and design</h4>Pancreatic cancer is a highly malignant tumor that is well known for its poor prognosis. Based on glycosylation, we performed integrated quantitative N-glycoproteomics to investigate the synergistic anti-tumor effects of aspirin and gemcitabine on pancreatic cancer cells and explore the potential molecular mechanisms of chemotherapy in pancreatic cancer.<h4>Methods and results</h4>Two pancreatic cancer cell lines (PANC-1 and BxPC-3) were treated with gemcitabine, asp ...[more]

PMID: 37639207

Similar Datasets

Multi-omics Study Reveals the Synergistic Anti-tumor Effects of Aspirin and Gemcitabine-based Chemotherapy on Pancreatic Cancer and the Underlying Mechanism

Project description:Pancreatic cancer is a highly malignant tumor that is well known for its poor prognosis. It has been reported that aspirin can reduce the risk of various cancers, but the potential role of aspirin and gemcitabine in pancreatic cancer pathogenesis and chemotherapy has not been studied. Therefore, we investigated their synergistic anti-tumor effects and explored the potential molecular mechanisms and biological functions underlying their inhibitory effects on the development of pancreatic cancer in the hope of identifying treatment-related or prognostic biomarkers for the effective treatment of pancreatic cancer.

2022-05-31 | PXD031910 | Pride

Multi-omics Study Reveals the Synergistic Anti-tumor Effects of Aspirin and Gemcitabine-based Chemotherapy on Pancreatic Cancer and the Underlying Mechanism

2023-09-08 | E-MTAB-11517 | biostudies-arrayexpress

Multi-omics Study Reveals the Synergistic Anti-tumor Effects of Aspirin and Gemcitabine-based Chemotherapy on Pancreatic Cancer and the Underlying Mechanism

Project description:Multi-omics Study Reveals the Synergistic Anti-tumor Effects of Aspirin and Gemcitabine-based Chemotherapy on Pancreatic Cancer and the Underlying Mechanism

| PRJEB51553 | ENA

Aptamer-Drug Conjugates-loaded Bacteria for Pancreatic Cancer Synergistic Therapy

Project description:Pancreatic cancer is one of the most malignant tumors with the highest mortality rates, and it currently lacks effective drugs. Aptamer-drug conjugates (ApDC), as a form of nucleic acid drug, show great potential in cancer therapy. However, the instability of nucleic acid-based drugs in vivo and the avascularity of pancreatic cancer with dense stroma have limited their application. Fortunately, VNP20009, a genetically modified strain of Salmonella typhimurium, which has a preference for anaerobic environments, but is toxic and lacks specificity, can potentially serve as a delivery vehicle for ApDC. Here, we propose an approach to synergistic therapy that utilizes the penetrative capability of bacteria and the targeting and toxic effects of ApDC by conjugating ApDC to VNP20009 via straightforward, one-step click chemistry. With this strategy, bacteria specifically target pancreatic cancer through anaerobic chemotaxis and subsequently adhere to tumor cells driven by the aptamer's specific binding. Results indicate that this method prolongs the serum stability of ApDC up to 48 hours and resulted in increased drug concentration at tumor sites compared to the free drugs group. Moreover, the aptamer's targeted binding to cancer cells tripled bacterial colonization at the tumor site, leading to increased death of tumor cells and T cell infiltration. Notably, by integrating chemotherapy and immunotherapy, the effectiveness of the treatment is significantly enhanced, showing consistent results across various animal models. Overall, this strategy takes advantage of bacteria and ApDC and thus presents an effective synergistic strategy for pancreatic cancer treatment.

2024-09-18 | GSE276051 | GEO

PRMT1 promotes pancreatic cancer development and resistance to chemotherapy

Project description:Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal types of cancer, and novel treatment regimens are direly needed. Epigenetic regulation contributes to the development of various cancer types, but its role in the development of, and potential as a therapeutic target for, PDAC remains underexplored. Here, we show that PRMT1 is highly expressed in murine and human pancreatic cancer and is essential for cancer cell proliferation and tumorigenesis. Deletion of PRMT1 delays pancreatic cancer development in a KRAS-dependent mouse model, and multi-omics analyses reveal that the PRMT1 depletion leads to global changes in chromatin accessibility and transcription, resulting in reduced glycolysis and a decrease in tumorigenic capacity. Pharmacological inhibition of PRMT1 in combination with gemcitabine has a synergistic effect on pancreatic tumor growth in vitro and in vivo. Collectively, our findings implicate PRMT1 as a key regulator of pancreatic cancer development and a promising target for combination therapy.

2024-03-09 | GSE223154 | GEO

PRMT1 promotes pancreatic cancer development and resistance to chemotherapy

2024-03-09 | GSE223152 | GEO

PRMT1 promotes pancreatic cancer development and resistance to chemotherapy

2024-03-09 | GSE223146 | GEO

PRMT1 promotes pancreatic cancer development and resistance to chemotherapy

2024-03-09 | GSE223133 | GEO

Aptamer-Drug Conjugates-loaded Bacteria for Pancreatic Cancer Synergistic Therapy

Project description:Aptamer-Drug Conjugates-loaded Bacteria for Pancreatic Cancer Synergistic Therapy

| PRJNA1154585 | ENA

The combination of cantharidin and anti-angiogenic therapeutics presents synergistic antitumor effects against pancreatic cancer

Project description:The combination of cantharidin and anti-angiogenic therapeutics presents synergistic antitumor effects against pancreatic cancer

| PRJNA459723 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data